Boardroom Alpha
Boardroom Alpha
AQST · Additional Proxy Materials (DEFA14A) · Filed April 24, 2026

Aquestive Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 24, 2026
Ticker
AQST
Accession
0001140361-26-016763
Boardroom Alpha · Filing insights

AQUESTIVE THERAPEUTICS urges shareholders to elect three directors, approve executive compensation, and ratify KPMG for 2026.

About Aquestive Therapeutics Inc
Market cap
$648M
1Y TSR
+11.0%
3Y TSR
+32.8%
Board grade
C+
Sector
Healthcare
CEO
Daniel Barber
Last annual meeting: Jun 10, 2026 · View full Aquestive Therapeutics Inc profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.    )

Filed by the Registrant
Filed by a Party other than the Registrant 
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under §240.14a-12

AQUESTIVE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 


 Your Vote Counts!  *Please check the meeting materials for any special requirements for meeting attendance.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V92180-P48218  AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE  WARREN, NJ 07059  AQUESTIVE THERAPEUTICS, INC.  2026 Annual Meeting  Vote by June 9, 2026  11:59 PM ET  You invested in AQUESTIVE THERAPEUTICS, INC. and it’s time to vote!  You have the right to vote on proposals being presented at the 2026 Annual Meeting of Stockholders. This is an important notice  regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2026 at 9:30 AM Eastern Time.  Get informed before you vote  View the 2026 Proxy Statement and 2025 Annual Report on Form 10-K online OR you can receive a free paper or email copy of the  material(s) by requesting prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote Virtually at the Meeting*  June 10, 2026  9:30 AM, Eastern Time  Virtually at: www.virtualshareholdermeeting.com/AQST2026 
 

 Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming stockholder meeting. You are encouraged to access and review the complete proxy materials. Please follow the instructions on the reverse side to access the proxy materials and to vote these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.  For All  Nominees:  Gregory B. Brown, M.D.  John S. Cochran  Abigail L. Jenkins  2. To approve, on a non-binding advisory basis, the compensation of our named executive officers.  For  3. To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.  For  4. To act upon any other matters that may properly come before the 2026 Annual Meeting or any adjournment or postponement thereof.  Voting Items  Board Recommends  V92181-P48218 
 



From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Aquestive Therapeutics Inc (AQST)

Reference

Frequently asked questions

When did Aquestive Therapeutics Inc file this DEFA14A?
Aquestive Therapeutics Inc (AQST) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001140361-26-016763.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
AQUESTIVE THERAPEUTICS urges shareholders to elect three directors, approve executive compensation, and ratify KPMG for 2026. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Aquestive Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Aquestive Therapeutics Inc has filed under CIK 1398733, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer